Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era: an extra challenge for healthcare institutions

Rawson, 2020, Antimicrobial use, drug-resistant infections and COVID-19, Nat Rev Microbiol, 18, 409, 10.1038/s41579-020-0395-y World Health Organization. Coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int/?gclid=Cj0KCQjwtMCKBhDAARIsAG-2Eu-HciJsbL9zoQLmRuqjZ4OIipukC9SSVRWdiY-iRG9IjgB9fqxMi1YaAhKSEALw_wcB [last accessed December 2021]. Neiva, 2020, Brazil: the emerging epicenter of COVID-19 pandemic, Rev Soc Bras Med Trop, 53, 1, 10.1590/0037-8682-0550-2020 Sharifipour, 2020, Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU, BMC Infect Dis, 20, 1, 10.1186/s12879-020-05374-z Perez, 2020, Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions – New Jersey, February–July, Morb Mortal Wkly Rep, 69, 1827, 10.15585/mmwr.mm6948e1 Bhatia, 2021, Creating political commitment for antimicrobial resistance in developing countries, Ind J Med Res, 83 Tiri, 2020, Antimicrobial stewardship program, COVID-19, and infection control: spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work?, J Clin Med, 9, 2744 Cieslinski, 2013, Molecular epidemiology characterization of OXA-23 carbapenemase-producing Acinetobacter baumannii isolated from 8 Brazilian hospitals using repetitive sequence-based PCR, Diagn Microbiol Infect Dis, 77, 337, 10.1016/j.diagmicrobio.2013.07.018 Arend, 2015, Molecular epidemiology of Klebsiella pneumoniae carbapenemase-producing Entero-bacteriaciae in different facilities in Southern Brazil, Am J Infect Control, 43, 137, 10.1016/j.ajic.2014.11.003 Tuon, 2011, Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?, J Infect, 62, 246 Tuon, 2015, Combined therapy for multi-drug-resistant Acinetobacter baumannii infection – is there evidence outside the laboratory?, J Med Microbiol, 64, 951, 10.1099/jmm.0.000144